Study Design and Inclusion Criteria of the EV-103 Study in Advanced Urothelial Carcinoma


Jonathan E. Rosenberg, MD, explains the study design and patient inclusion criteria of the phase 2 EV-103 study investigating combination enfortumab vedotin plus pembrolizumab for the treatment of patients with metastatic or locally advanced urothelial carcinoma.

Related Videos
Related Content